SCHEMBL32690705

SCHEMBL32690705

Cc1ccccc1-c1[nH]c2ccc(/C=C/C(=O)NO)cc2c(=O)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 18/20 0.48
▸ HDAC2 Q92769 11/20 0.48
▸ HDAC6 Q9UBN7 11/20 0.48
▸ HDAC10 Q969S8 9/20 0.48
▸ HDAC11 Q96DB2 9/20 0.48
▸ HDAC8 Q9BY41 9/20 0.48
▸ HDAC4 P56524 9/20 0.48
▸ HDAC3 O15379 8/20 0.48
▸ HDAC7 Q8WUI4 8/20 0.48
▸ HDAC9 Q9UKV0 8/20 0.48
▸ HDAC5 Q9UQL6 8/20 0.48
▸ NCOR2 Q9Y618 2/20 0.48
▸ MEF2D Q14814 1/20 0.44
▸ KCNH2 Q12809 2/20 0.44
▸ TET3 O43151 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ FOXO1 Q12778 1/20 0.43
▸ TET2 Q6N021 1/20 0.43
▸ PIK3C3 Q8NEB9 1/20 0.43
▸ TET1 Q8NFU7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32690820 0.88 HDAC1 (0.44) HDAC1HDAC2HDAC6HDAC10HDAC11
SCHEMBL32690804 0.88 CCNB2 (0.44) HDAC1HDAC6HDAC3APP
SCHEMBL32690654 0.87 HDAC1 (0.47) HDAC1HDAC2HDAC6HDAC10HDAC11
SCHEMBL32690677 0.85 HDAC1 (0.42) HDAC1HDAC2HDAC6HDAC10HDAC11
SCHEMBL32690855 0.77 AR (0.46) —
SCHEMBL32690840 0.77 HDAC1 (0.42) HDAC1HDAC2HDAC6HDAC10HDAC11
SCHEMBL32690795 0.76 CCNB2 (0.45) APP
SCHEMBL32690687 0.76 EPHX2 (0.48) HDAC1HDAC6HDAC3APP
SCHEMBL12425753 0.76 HDAC1 (0.61) HDAC1HDAC2HDAC6HDAC10HDAC11
SCHEMBL32690798 0.75 PARP1 (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085046-A1 Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition TAIWANJ PHARMACEUTICALS CO LTD (TW) 2026-03-26 — — US claimed
US-20260085046-A1 Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition TAIWANJ PHARMACEUTICALS CO LTD (TW) 2026-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085046-A1 Dual Function Compounds For NADPH Oxidase Inhibition And Histone Deacetylase Inhibition NOX1, NOX4, CYBB HDAC1 7/4885HDAC2 12/4885HDAC6 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback